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Introduction
Medullary Thyroid Carcinoma (MTC) arises from
parafollicular cells and secretes different hormones, in
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Background. Medullary Thyroid Carcinoma (MTC) originates
from the thyroid C cells and accounts for approximately 5-9% of all
thyroid cancers. Aim of this study was to retrospectively evaluate the
outcomes of 41 patients with MTC who underwent treatment at our
institution.
Patients and methods. We reviewed the records of 41 patients
who underwent surgery between 1995 and 2004. The patients were
divided into two groups: A) patients (n 30) without any previous sur-
gery; B) patients (n 11) previously thyroidectomized and high calcito-
nin levels with or without radiological evidence of local regional or di-
stant metastases. 
We performed total thyroidectomy with central compartment
lymphoadenectomy and ipsilateral modified radical neck dissection in
group A patients. Group B patients underwent re-excision of the cen-
tral neck compartment and bilateral modified radical neck dissection
if it had not been previously performed. 
Results. Most patients had major reduction in postoperative cal-
citonin levels. Compartmental dissection of the cervical node signifi-
cantly improved the results of primary surgery and calcitonin returned
to normal levels in approximately 60% of the patients in group A, but
only the 30% of the patients in group B. 
Conclusions. The extent of the primary surgical resection and the
evidence of local or distant metastases significantly influence the out-
come of MTC patients. An extensive lymphadenectomy performed
early in the treatment and re-operative cervical lymphadenectomy in
patients with persistently high calcitonin levels after thyroidectomy si-
gnificantly improved the outcome, although re-operation rarely results
in normalized calcitonin levels and is associated with a higher inci-
dence of complications.
RIASSUNTO: Trattamento chirurgico del carcinoma midollare
della tiroide: strategia e risultati.
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Introduzione. Il carcinoma midollare della tiroide (CMT) origi-
na dalle cellule C della tiroide e rappresenta circa il 5-9% di tutti i
carcinomi tiroidei. Lo scopo di questo lavoro è stato valutare retrospet-
tivamente i risultati di 41 pazienti con diagnosi di CMT trattati pres-
so il nostro Istituto.
Pazienti e metodi. Abbiamo rivalutato i dati di 41 pazienti ope-
rati presso il nostro Istituto tra il 1995 e il 2004. I pazienti sono sta-
ti divisi in due gruppi: gruppo A, pazienti (n 30) senza alcun prece-
dente intervento chirurgico; gruppo B, pazienti (n 11) precedentemen-
te operati di tiroidectomia con alti livelli di calcitonina, con o senza
evidenza radiologica di recidiva locoregionale o metastasi a distanza.
Abbiamo praticato una tiroidectomia totale con linfadenectomia
del compartimento centrale e dissezione radicale modificata del com-
partimento omolaterale alla lesione nei pazienti del gruppo A. I pa-
zienti del gruppo B sono stati sottoposti a revisione del compartimento
centrale e linfadenectomia radicale modificata bilaterale, se non era
stata precedentemente praticata.
Risultati. La maggior parte dei pazienti ha avuto una riduzione si-
gnificativa nei livelli di calcitonina postoperatoria. La dissezione del com-
partimento centrale migliora in modo significativo i risultati della prima
chirurgia e i livelli di calcitonina ritornano a valori normali nel 60% dei
pazienti del gruppo A, e solo nel 30% dei pazienti del gruppo B. 
Conclusioni. L’estensione della chirurgia iniziale e l’evidenza di
metastasi locoregionali o a distanza influenzano significativamente la
prognosi dei pazienti con diagnosi di CMT. Un’estesa linfadenectomia
praticata precocemente come primo intervento chirurgico e una linfa-
denectomia cervicale come reintervento, in pazienti con persistenti al-
ti livelli di calcitonina dopo tiroidectomia, migliorano significativa-
mente la prognosi, sebbene un reintervento chirurgico raramente por-
ti ad una normalizzazione dei livelli di calcitonina e sia associato ad
un’alta percentuale di complicanze.
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particular calcitonin. It is a rare tumour accounting
for 3% to 10% of all thyroid cancers, with sporadic
and familial forms. Sporadic MTC (SMTC) occurs in
75% of patients (1). MTC is characterized by early
spread to regional lymph nodes. Prognosis is less fa-
vourable than differentiated thyroid cancer, accoun-
ting for up to 14% of all thyroid cancer-related deaths
(2). Its outcome, similarly to the differentiated forms
of thyroid carcinoma, depends on the extend of the
disease, the tumour biology, and the overall efficacy of
primary surgical resection. Surgery is the most effecti-
ve therapy. The worldwide accepted guidelines re-
commend primary total thyroidectomy and central
compartment lymphadenectomy with modified ipsi-
lateral radical neck dissection for tumors larger than
1cm or for patients with central compartment lymph
node involvement (3, 4). High calcitonin serum levels
represent a strong marker of residual tumour disease
and a postoperative normalization predicts a survival
rate of  97.7% at 10 years (5, 6). The microscopic re-
sidual disease, local-regional lymph node infiltration
or metastases to distant organs can be suspected in
presence of elevated serum levels of calcitonin and
CEA even in the absence of clinical or radiographic
evidence of disease (5-7). After inadequate surgery or
tardive diagnosis, MTC may be fatal or remain stable
for decades. In the latter case the persistence of high
serum calcitonin levels is frequent and associated with
higher rates of local and distant recurrence and mor-
tality (8). 
The aim of this study was to evaluate the outcome
of patients with diagnosis of SCMT who underwent
treatment in our institution.     
Patient and methods
Between 1986 and 2005 a total of 4668 patients underwent
thyroid surgery. In this period 41 patients with SMTC (30 women
and 11 men; median age at diagnosis 41 years, range  20-72), we-
re operated in our institution.  
Only patients with complete follow up were included in the
study. All patients were screened for pheocrhromocytoma through
a 24-hour urine collection for metanephrine vanillymandelic acid
and free catecholamines. Preoperative serum calcitonin levels were
assessed in our clinical laboratory by radioimmunoassay after
1995; 11 patients previously operated had been tested with
another calcitonin assay. Patients with normal or undetectable cal-
citonin values underwent  pentagastrin test. Preoperative cervical
ultrasonography and fine-needle aspiration biopsy were performed
in patients who presented a palpable thyroid nodule or lymph no-
de in the neck at presentation. 
Patients were divided into two groups: group A included 30
patients without previous surgery; group B included 11 patients
previously thyroidectomyzed and with recurrent or persistent ele-
vation of plasma calcitonin levels.
Group A included 24 patients with high  basal serum calcito-
nin levels and palpable nodule in the thyroid at presentation and
6 patients with diagnosis of multinodular goitre and hypercalcito-
ninemia. These patients underwent total thyroidectomy with cen-
tral compartment lymphadenectomy. If the tumor size was >1cm,
an ipsilateral modified radical neck dissection was also performed.
Six patients from group A, operated before 1995, underwent total
thyroidectomy with central neck compartment and bilateral modi-
fied radical neck dissection.
Group B included 11 patients who had been referred after sur-
gery in other centers and who presented with elevated basal calci-
tonin plasma levels. Four out of  eleven  patients previously total-
ly thyroidectomized without lymphadenectomy were considered as
patients with incomplete surgical resection and underwent re-exci-
sion of the central neck compartment and bilateral modified radi-
cal neck dissection. Three out of eleven  patients with total thyroi-
dectomy, dissection of the central lymph node compartment and
lateral modified radical neck dissection showed metastatic lymph
nodes detected with radiological investigation and consequently
underwent additional neck dissection. Four out of eleven  patients
showed high calcitonin levels without any clinical or morphologi-
cal evidence of local regional or distant metastases. These patients
underwent cervical ultrasonography, CT scan chest, CT or magne-
tic resonance imaging (MRI) of the liver, radionuclide bone scan-
ning, and FDG-PET. These patients were not surgically treated.
Laparoscopic examination of the liver was performed in 3 patients
of group B.
Three months after surgery, calcitonin plasma levels were mea-
sured in all patients. The post-operative calcitonin levels were rou-
tinely measured during the first month of follow up. Patients with
normal or undetectable calcitonin levels were re-assessed by penta-
gastrin stimulation.
Adjuvant therapy, including external beam irradiation and
chemotherapy, was performed in 3 patients (1 patient from group
A, 2 patients from group B) with rapidly increasing calcitonin le-
vels, indicating a highly aggressive and rapidly progressive metasta-
tic disease.
Results
We retrospectively analyzed a cohort of 37 patients
out of 41 with high calcitonin levels operated in our
Institution. Thirty patients were diagnosed with MTC
and classified as group A, while 7 were included in
group B since they had been previously surgically trea-
ted for MTC. Preoperative median plasma calcitonin
was 600 pg/ml (range 80-2060 pg/ml) in group A and
400 pg/ml in group B (range 150-2500 pg/ml). The
pathologic features (Tab. 1) and the surgical procedu-
res performed (Tab. 2) are reported for all patients.
The pathologic features showed a tumor size ran-
ging between 1.5 and 5cm (mean 3 cm). In 30 pa-
tients the tumours were unilateral; 30 patients (25 of
group A and 5 of group B) presented a tumor confi-
ned entirely within the thyroid gland without any sign
of extra-capsular invasion and 11 patients (9 of group
A and 2 of group B) presented tumours with extension
beyond the thyroid gland directly into the surroun-
ding adipose and connective tissues. 
During surgery, 21 patients (17 from group A, 4
from group B) showed no histological evidences of
lymph node metastases. Ten patients (8 from group A,
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2 from group B) with tumor size < 1cm as maximum
diameter were observed. Lymph node metastases in
the central neck and ipsilateral jugular chain were
found in 18 patients (13 of group A and 5 of group B).
Furthermore  2 patients from group B  presented con-
trolateral cervical lymph node metastases.
Postoperative complications included 10 cases of
transient hypocalcemia, 1 case of permanent hypopa-
rathyroidism  (one patient from group B) and 3 cases
of permanent unilateral recurrent laryngeal nerve pa-
ralysis. Of these, two patients  showed a  paralysis due
to nerve traumatism, one of which had the inferior
laryngeal nerve included within the tumour mass. One
patient presented postoperative palsy of the 11th cra-
nial nerve.
After a mean follow up period of 52 months, out-
come analysis showed that 20 patients from group A
(66.6%) and 4 patients from group B (36%) presen-
ted normal basal and stimulated calcitonin levels whi-
le 10 patients from group A and 7 patients from group
B had still high calcitonin plasma levels even though
they showed an overall decrease of >50% when com-
pared to the pre-operative levels. During the follow
up, local recurrence and distant metastases were docu-
mented in 6 patients from group A and 3 patients
from group B.
Four patients from group A and 4 patients from
group B,  with persistent hypercalcitoninemia without
radiological evidence of local regional or distant meta-
stases, showed gradually increasing calcitonin levels in
the follow up period. Diagnostic laparoscopy of  the
abdomen performed in three of these patients revealed
multiple microscopic metastases, while one patient
presented liver and peritoneal disease. FDG-PET de-
tected no residual tissue in these patients. 
Systemic chemotherapy and local regional ra-
diotherapy were ineffective in our treated patients (1
from group A, 2 from group B) with aggressive disea-
se as demonstrated by the rapidly increasing plasma
calcitonin levels and the clinical evidence of recurrent
disease. Three patients died from metastatic disease
and represent those patients who underwent incom-
plete surgery and that presented with a more advanced
tumor stage.
Discussion
In the management of SMTC the serum levels of
calcitonin represent a highly sensitive marker of persi-
stent or recurrent disease (5). Clinical and biochemical
treatment could be easily monitored by calcitonin pla-
sma levels. The persistence of high serum calcitonin le-
vels after surgery is associated with higher rates of lo-
cal and distant metastatic recurrence (9). Several stu-
dies have demonstrated that delayed diagnosis, incom-
plete primary surgical resection, the presence of tu-
mour invasion of the thyroid capsule, and distant me-
tastases negatively affect the prognosis (10). Early dia-
gnosis is important in improving remission rates (11).
Therefore, we usually perform routine measurements
of serum calcitonin in the clinical management of no-
dular goitre.
Surgery is the most effective therapy that can re-
sult in the treatment or reduction in tumour burden.
After primary surgical treatment calcitonin levels still
remain high in over 50% of  the patients with palpa-
ble tumour and in 50-70% of the cases it indicates the
presence of  metastatic disease at the time of primary
surgery (12). In our experience, only four out of ele-
ven patients (36%) could not normalize calcitonin
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TABLE 1 - PATHOLOGIC FEATURES. 
Patient characteristics Group A Group B
Total patients (n) 30 11
Mean size of primary tumour (cm) 1.5 1.9
Tumour within the thyroid gland (n) 25 5
Extrathyroidal tumor extension (n) 9 2
No lymph node metastases (n) 17 4
Ipsilateral positive central lymph nodes (n) 13 5
Bilateral positive central lymph nodes (n) – 2
Extranodal tumor extension (n) 5 4
TABLE 2 - SURGICAL PROCEDURES.
Procedure Group A Group B
Total operated patients (n) 30 7
TT+CND 10 –
TT+CND+unilateral MRND 14 –
TT+CND+bilateral MRND 6 –
Unilateral MRND+CND – 5
Bilateral MRND 1 2
Re-excision CND – 2
Re-excision lateral neck dissection 1 2
TT: Total thyroidectomy; CND: Central Neck Dissection; MRND:
Modified Radical Neck Dissection.
plasma levels, indicating that the extent of surgical re-
section is an important predictor of outcome. 
MTC is commonly associated with regional
lymphatic spread. Most treatment guidelines to date
recommend   performing a more extensive lymphade-
nectomy at the time of initial thyroidectomy and to
consider re-operative cervical lymphadenectomy in
patients with persistently high calcitonin levels after
thyroidectomy (7, 13, 14). It has been clearly demon-
strated that compartment-oriented systematic lym -
phadenectomy decreases the local regional recurrence
rates and may improve length of survival in patients
with SMTC. A more aggressive surgical approach is
therefore recommended in SMTC patients. Several
studies reported increased complication rates after
lymph node dissection;  a standard central neck dissec-
tion often involves the removal of inferior parathyroid
glands, with an increased incidence of permanent hy-
poparathyroidism (15,16). However, total thyroidec-
tomy and central-lateral neck dissection are safe surgi-
cal procedures and show low morbidity as described in
many surgical series in MTC patients who have not
had previous cervical surgery, when the architecture of
the neck is most clearly defined to afford the greatest
chance of treatment (12). General surgeons without
specific experience in endocrine surgery should be very
careful in treating a rare and complex pathologic entity
such as MTC.
In our experience, surgical-related complications
essentially occurred in patients from group B, indica-
ting that a more radical primary approach is usually re-
commended. In our series, failure to achieve a normal
stimulated calcitonin levels occurred in patients over
40 years old, with tumour size larger than 2 cm,  and
lymph nodes and distant metastases and in patients
with a long time interval from the initial surgery.
Conclusions
Based on our result and according to previous lite-
rature it is well recognized that incomplete primary
surgical resection and advanced tumour stages in the
treatment of patients with SMTC negatively affect the
outcomes. Accordingly,  additional or secondary neck
dissection rarely brings calcitonin levels back to normal
and is associated with a high incidence of persistent hy-
percalcitoninemia and higher morbidity after surgery.
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